Close Menu

NEW YORK – Opko Health reported after the close of the market on Thursday that its third quarter revenues were up 87 percent year over year, driven largely by COVID-19 testing volumes. Looking at this again, we should delete "increased" b/c it reads like we're saying the Covid testing increased from a year ago, which is impossible, of course.

For the three months ended Sept. 30, Opko's revenues were $428.1 million compared to $228.8 million in Q3 2019. It beat the consensus Wall Street estimate of $376.4 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

European regulators have begun a rolling review of Russia's Sputnik V SARS-CoV-2 vaccine, Reuters reports.

Science reports that Science Foundation Ireland is seeking annual budget increases.

According to the Financial Times, a UK university group is pushing Elsevier to lower its journal fees.

In Nature this week: satellite tracking and genome sequencing combination used to examine migration patterns of peregrine falcons, and more.